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Bronchopulmonary dysplasia (BPD) is one of the most common health complications of
premature birth. Corticosteroids are commonly used for treatment of BPD, but their use
is challenging due to variability in treatment response. Previous pharmacometabolomics
study has established patterns of metabolite levels with response to dexamethasone.
We obtained additional patient samples for metabolomics analysis to find associations
between the metabolome and dexamethasone response in a validation cohort. A total
of 14 infants provided 15 plasma and 12 urine samples. The measure of treatment
response was the calculated change in respiratory severity score (deltaRSS) from preto-post treatment. Each metabolite was assessed with paired analysis of pre and
post-treatment samples using Wilcoxon signed rank test. Correlation analysis was
conducted between deltaRSS and pre-to-post change in metabolite level. Paired
association analysis identified 20 plasma and 26 urine metabolites with significant
level difference comparing pre to post treatment samples (p < 0.05). 4 plasma and
4 urine metabolites were also significant in the original study. Pre-to-post treatment
change in metabolite analysis identified 4 plasma and 8 urine metabolites significantly
associated with deltaRSS (p < 0.05). Change in urine citrulline levels showed a similar
correlation pattern with deltaRSS in the first study, with increasing level associated
with improved drug response. These results help validate the first major findings from
pharmacometabolomics of BPD including key metabolites within the urea cycle and
trans-4-hydroxyproline as a potential marker for lung injury. Ultimately, this study furthers
our understanding of the mechanisms of steroid response in BPD patients and helps to
design future targeted metabolomics studies in this patient population.
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The growing field of pharmacometabolomics has emerged
as a powerful method for furthering the understanding of
mechanisms contributing to variability in drug response for
many different fields of medicine. The patient metabolome can
be measured at both pretreatment and post-treatment periods
of care. Ideally, the metabolome measured pretreatment and a
difference in the metabolome measured post-treatment, can help
illustrate the metabolic mechanisms of variable drug response.
These metabolome baseline measurements and changes could
potentially serve as signatures for predicting drug response and
be used clinically to help determine the likelihood of drug
response prior to treatment or early in the treatment course.
Furthermore, if these metabolome changes can be replicated
in multiple studies, the evidence for a mechanistic relationship
between metabolism and drug response is strengthened, and the
potential for a predictive metabolic signature of drug response is
further supported.
We previously conducted a pharmacometabolomics study
on a pilot cohort of preterm infants less than 32 weeks
gestation at birth who received dexamethasone treatment for
BPD (5). Our results showed metabolites with a significant
difference in abundance when comparing pretreatment to
post-treatment metabolite levels. In order to validate the

INTRODUCTION
Bronchopulmonary dysplasia (BPD) is a lung disease occurring
in preterm infants resulting from lung structure immaturity,
ventilator-associated lung injury and inflammation. In the US,
BPD is one of the most common complications of premature
birth with approximately 18,000 infants impacted annually
(1). This accounts for approximately 25% of infants with
birth weight lower than 1,500 g (2–4). Despite the high rate
of occurrence in the preterm infant population, there is no
FDA approved treatment indicated for BPD. Corticosteroids
are commonly used for prevention or management of BPD
symptoms. Dexamethasone is a glucocorticoid that is used
primarily for its anti-inflammatory and immunosuppressant
effects. In cases of bronchopulmonary dysplasia, dexamethasone
helps facilitate weaning from the ventilator. Common side effects
of dexamethasone in pre-term infants can include hyperglycemia,
hypertension, and GI bleeding/perforation. Unfortunately, there
are a number of difficulties associated with corticosteroid use
in preterm infants. This can include interpatient variability
in treatment response and clinical effects. Compounding this
variability in treatment response, there are no predictive factors
that can help determine which patients will respond to treatment.

TABLE 1 | Demographics and respiratory data.
Discovery cohort data
Patient #
Median
IQR

GA (weeks)

BW (g)

Race

DOL steroid started

Pre-RSS

Post-RSS

deltaRSS

Plasma sample

Urine sample

25 0/7

663

–

36

6.48

2.6

–2.3

–

–

24 2/7-26 0/7

465–790

–

27–115

4.29–9.02

1.86–3.21

–5.32 to –1.79

–

–

BW (g)

Race

DOL steroid started

Pre-RSS

Post-RSS

deltaRSS

Plasma sample

Urine sample

Replication cohort data
Patient #

GA (weeks)

11

25 3/7

704

AA

17

10.32

2.84

–7.48

X

–

12

24 3/7

1,000

WH

18

6.02

3.66

–2.36

X

X

13

29 3/7

1,330

WH

27

10.8

11.5

0.7

X

X

14

24 1/7

510

WH

49

15

3.7

–11.3

X

U

15

25 3/7

840

AA

158

5.7

3.37

–2.33

X

X

16

25 3/7

510

AA

40

14.08

3.69

–11.11

X

X

17

25 0/7

820

O

29

11.76

2.76

–9

X

X

17-2

25 0/7

820

O

61

7.7

2.1

–5.6

X

U

18

25 2/7

879

WH

25

5.17

2.5

–2.67

X

X

20

23 1/7

580

AA

15

5.28

6.54

1.26

–

X

21

24 6/7

660

WH

24

7.56

5.27

–2.29

X

–

22

24 6/7

970

WH

41

6.6

2.8

–3.8

X

X

23

24 2/7

765

WH

30

6.24

7.16

0.92

X

X

23-2

24 2/7

765

WH

104

5.48

8.54

3.06

X

X

24

24 1/7

680

AA

29

7.95

3.29

–4.66

X

X

25

26 2/7

1,090

WH

88

3.57

0.5 (NC)

–3.07

X

X

0.7027

0.3512

–

0.3441

0.2572

0.1580

0.9837

–

–

*T-test
p-value

AA, African American; BW, birthweight; DOL steroid, day of life (age) when infant started steroids; GA, gestational age at birth; IQR, interquartile range; NC, Nasal Canula;
O, Other; RSS, Respiratory Severity Score; U, Post treatment samples unavailable; WH, white. Negative deltaRSS indicates improved lung function.
*T-test comparing demographics and baseline data between discovery and validation cohorts.
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FIGURE 1 | Change in clinical outcome and metabolite abundance from pretreatment to post-treatment. (A) Boxplots showing the change in respiratory severity
score in patients with collected plasma and urine samples. (B) Bar graph showing the change in xylitol as an example metabolite. Metabolite abundance is displayed
with arbitrary units of measurement.

initial findings and confirm metabolites for future targeted
analyses in larger cohorts, we obtained additional patient
samples for pharmacometabolomics analysis. Our goal with
this analysis is to conduct a replication cohort dexamethasone
pharmacometabolomics study on preterm infant urine and
plasma samples in order to identify and confirm metabolic
changes associated with drug response.

infants less than 32 weeks gestation at birth and treated with
systemic dexamethasone per clinical care were eligible for
enrollment. Essentially all infants were requiring substantial
ventilatory support, either intubated or via non-invasive assisted
ventilation. Exclusion criteria included any patients with an
active infection (the DART (Dexamethasone: A Randomized
Trial) course was deferred until infection was resolved),
coexisting significant structural heart disease, non-prematurity
related cause of their pulmonary disease, complex structural,
or known genomic differences, and congenital difference in
lung or airways development. Patient demographics and clinical
data were obtained from the clinical chart and by speaking
with bedside clinicians. For this analysis, we used data from
the first course of systemic dexamethasone for each child,
as well as data from the second course of dexamethasone
from two patients.
The DART course was used at our institution to standardize
dexamethasone dosing for BPD. The course consisted of

MATERIALS AND METHODS
Subjects and Study Design
Subject enrollment and study design followed the protocol
described previously (5). To summarize, this replication cohort
study was conducted under the approval by the Children’s
Mercy Hospital institutional review board (IRB) prior to
patient enrollment. Parental consent was obtained in accordance
with IRB regulations. Starting in October 2016, all preterm
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0.15 mg/kg/daily for 3 days, then 0.1 mg/kg/day for 3 days,
then 0.05 mg/kg/day for 2 days, then 0.02 mg/kg/day for
2 days. The total dose was 0.89 mg/kg. Clinical outcome was
measured as short-term phenotypic response to dexamethasone.
The Respiratory Severity Score (RSS = mean airway pressures x
FiO2) was calculated prior to treatment (baseline) and on day 7 of
treatment (drug response). In order to account for intraindividual
variability, the average RSS for a 24-h period was collected. RSS
was calculated as the mean airway pressure × fraction of inspired
oxygen (FiO2) (ranging from 21 to 100%).
Blood and urine samples were collected two times, once in the
24 h prior to starting systemic dexamethasone (pre-treatment)
and again at day 3–6 after starting systemic dexamethasone (posttreatment). Post-treatment blood and urine sample collection
timing was conducted during the steroid course and determined
by and paired with scheduled blood draws for clinical labs within
the target window. Samples were collected in the NICU and
then either briefly refrigerated or immediately processed. Urine
and plasma samples were aliquoted and stored at –80◦ C until
metabolomic assay.

TABLE 2 | List of metabolites significantly associated with pre-post
dexamethasone treatment comparison.
Metabolites

Fold change

Direction

P-valuea

Plasma
Xylitol

0.73647

Down

0.0002

Kynurenine

0.62206

Down

0.0006

Hypoxanthine

4.0073

Up

0.0009

Urea

1.451

Up

0.0015

5-Hydroxymethyl-2-furoic acid

0.55663

Down

0.0043

Pseudo uridine

0.79005

Down

0.0054

P-Hydroxylphenyllactic Acid

0.64733

Down

0.0067

Gluconic acid lactone*

0.45612

Down

0.0103

Ribitol

0.81318

Down

0.0103

Uracil

0.86725

Down

0.0103

Xylulose

0.71414

Down

0.0103

Uric acid

1.2145

Up

0.0151

Uridine

1.3129

Up

0.0151

Xylose

0.85594

Down

0.0151

Ethanolamine

0.66029

Down

0.0181

Threonine

0.73213

Down

0.0181

Inosine

3.3745

Up

0.0215

Untargeted Metabolic Assessment

Serine

0.8359

Down

0.0256

Trans-4-hydroxyproline

0.6678

Down

0.0256

Butane-2,3-Diol

1.7161

Up

0.0413

P-hydroxylphenyllactic acid

0.46969

Down

0.0005

Oleic acid

1.4567

Up

0.0010

Methods for metabolomics analysis were described previously
(5). Briefly, plasma and urine samples were submitted
for untargeted metabolomics analysis to the West Coast
Metabolomics Center at UC Davis. Untargeted metabolomics
profiling was performed using an Agilent 7890A gas
chromatograph and a Leco Pegasus IV time-of-flight mass
spectrometer. BinBase database was used to identify metabolites
by retention index, align mass spectra, and perform gap filling.
Data was reported as mass spectral peak height.

Urine

Xylitol

0.69276

Down

0.0010

Glycyl-proline

0.56812

Down

0.0010

Proline

0.34309

Down

0.0015

1.328

Up

0.0024

Aminomalonate

0.47598

Down

0.0024

Phthalic acid

0.66116

Down

0.0049

Creatinine

0.57385

Down

0.0049

Palmitic acid

Phenol

1.9054

Up

0.0068

Orotic acid

0.85041

Down

0.0068

3-Hydroxypropionic acid

0.68286

Down

0.0068

Threonine

0.39941

Down

0.0068

5-Hydroxymethyl-2-furoic acid

0.51825

Down

0.0093

Citric acid

0.64898

Down

0.0161

Stearic acid

1.3958

Up

0.0210

Glycine

0.55962

Down

0.0210

Pipecolinic acid

0.47561

Down

0.0210

Aspartic acid

0.47046

Down

0.0210

Methionine

0.70898

Down

0.0269

Thymine

0.68841

Down

0.0269

Kynurenine

0.5464

Down

0.0269

Threitol

1.1266

Up

0.0342

1-Methylinosine

0.82274

Down

0.0342

Phenylalanine

0.73404

Down

0.0342

Citramalic acid

1.2848

Up

0.0425

Statistical Analysis
Peak height values were subjected to data preprocessing prior to
analysis. Missing value estimation was performed by removing
metabolites with more than 30% of values missing among the
patient samples. Any remaining missing values were replaced
with a calculated small value (half of the minimum positive
value for that metabolite reported in the raw data). Further data
processing also included normalization by sum peak intensity of
all known metabolites as well as log transformation. Categorical
statistical analysis was performed on the MetaboAnalyst 5.0
platform (6). Patient pretreatment and post-treatment samples
were paired for categorical analysis. The difference in metabolite
abundance pre and post-treatment was tested using Wilcoxon
signed rank test. Boxplots created from the data analysis featured
quartiles 1 and 3 at the bottom and top of the box, respectively.
Boxplot features included a horizontal line representing the
median, an upper whisker of Q3 + 1.5∗ IQR and a lower whisker
of Q1 – 1.5∗ IQR. Significance threshold was set at p-value < 0.05.
Adjustment for multiple comparisons was done using Benjamini
and Hochberg’s false discovery rate method. Statistical analysis
on change in metabolite level and RSS values was performed
using Pearson correlation analysis. Correlation analysis was
conducted to determine if changes in metabolite abundance from
pretreatment to post-treatment was associated with change in

Bold, Metabolite found significant in pre-post comparison for both discovery and
replication cohorts.
a P-value included in the table is unadjusted for multiple comparisons.
*Discovery cohort showed significant association with free gluconic acid form in
serum and lactone form in urine.
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FIGURE 2 | Boxplots displaying the pre-to-post-treatment difference in abundance for the replicated metabolites in (A) plasma and (B) urine between the discovery
and replication cohort studies. Metabolite abundance is displayed with arbitrary units of measurement. Yellow dots represent the group mean.

p-hydroxyphenyllactic acid. One significant metabolite, gluconic
acid lactone, was significant in the free acid form in the serum
analysis of the previous study, but also significant in the lactone
form in the urine sample regression analyses of deltaRSS.
In urine samples, 26 metabolites were found to be statistically
significantly different between pretreatment and post-treatment
samples. Among these significant metabolites, four were
replicated with the results of the same analysis conducted in the
discovery cohort study. These metabolites are 5-hydroxymethyl2-furoic acid, pipecolinic acid, kynurenine, and 1-methylinosine.
The significant results from both plasma and urine sample
analysis are included in Table 2. The pre to post treatment
comparison of replicated metabolite abundances are shown in
Figure 2.
Correlation analysis was conducted to determine if change
in metabolite abundance was associated with change in RSS
(clinical response). Analysis of plasma samples identified four
metabolites with statistically significant association. Urine sample
analysis identified eight metabolites with statistically significant
association. Significant results from the analysis of plasma
and urine samples are shown in Table 3. Among these
significant metabolites, change in urine levels of citrulline
showed a significant association with change in RSS score

RSS, representing clinical response to dexamethasone therapy.
Significance threshold was set at p-value < 0.05.

RESULTS
In this replication cohort, 14 infants provided 15 matched
pretreatment and post-treatment plasma samples and 12
matched pretreatment and post-treatment urine samples. Two
patients, 17 and 23, provided multiple samples from both first
and second rounds of treatment with dexamethasone. Detailed
demographic information for the patient cohort is provided in
Table 1. Comparison of pretreatment and post-treatment RSS
values for plasma and urine samples are shown in Figure 1.
A total of 690 metabolites were measured in plasma and
urine samples. Within this metabolite set, 135 metabolites
were identified in plasma samples and 178 were identified
in urine samples. Categorical analysis of pretreatment vs.
post-treatment plasma samples identified 18 metabolites with
statistically significant difference in abundance comparing pre
and post-treatment. Among these significant metabolites, three
were replicated from the same analysis in the pilot cohort.
These metabolites are xylitol, trans-4-hydroxyproline, and
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DISCUSSION

TABLE 3 | Metabolites with change in abundance significantly associated
with change in RSS.
Metabolites

Correlation coefficient

p-value

Octadecanol

0.572

0.026

Phosphoethanolamine

0.571

0.026

Methionine

–0.541

0.037

Maltotriose

0.519

0.048

Adequate therapy for BPD prevention or treatment continues to
be a major challenge in neonatology. Response to dexamethasone
therapy, a common drug used clinically, shows high interpatient
variability and is highly unpredictable. As we saw in our previous
study, we again observe a wide range of clinical response within
our replication cohort with a group of responders and nonresponders. There are a variety of proposed mechanisms for
the variable response to steroids in this patient population,
and many of them involve metabolic activity and pathways.
Pharmacometabolomics is an emerging powerful tool for
effectively capturing the differences in metabolite levels between
patients that can be linked to differences in treatment response. In
our previous cohort study, we showed a number of metabolites
and their relevant pathways that were significantly associated
with treatment outcomes in BDP patients. In this replication
cohort study, we are once again able to show a substantial
number of metabolites associated with treatment response, with
several of these metabolites showing overlap between the pilot
and replication cohorts.
Among the replicated metabolomics results between our
analyses of metabolite abundance affected by dexamethasone
therapy, trans-4-hydroxyproline is one the most extensively
discussed and relevant to BPD pathophysiology. In the prior
study and this study, trans-4-hydroxyproline was found to
be decreased in serum following dexamethasone treatment.
Previous studies have identified trans-4-hydroxyproline as
elevated in patients with idiopathic pulmonary fibrosis,

Plasma

Urine
Citrulline

–0.703

0.003

2-Picolinic acid

0.678

0.005

Methylmaleic acid

0.638

0.010

Isoleucine

0.593

0.020

Sorbitol

–0.559

0.030

Indole-3-acetate

0.557

0.031

Aminomalonate

0.548

0.035

2,4-Hexadienedioic acid

0.540

0.038

Bold, Metabolite found significant in correlation analysis for both discovery and
replication cohorts.

in both the original and replication cohort studies. Both
association analyses also showed the same directional trend,
with a positive change in RSS score (indicating poor response
to therapy) associated with significantly lower levels of urine
citrulline. Correlation plots of the top three most significant
metabolites in plasma and urine samples are shown in
Figure 3.

FIGURE 3 | Results of correlation analysis for change in metabolite level with change in Respiratory Severity Score (RSS). The three metabolites with the most
significant correlation in (A) plasma and (B) urine samples are shown. Metabolite abundance is displayed with arbitrary units of measurement.
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levels with clinical response grouping of BPD patients, with
lower levels of citrulline also associated with poorer response
to therapy. Citrulline is produced through arginine catabolism
as a byproduct of nitric oxide synthesis catalyzed by nitric
oxide synthases. Citrulline can also serve as a precursor to
arginine as the reactions are bidirectional. Several studies have
proposed a link between citrulline and the urea cycle with
BPD and pulmonary hypertension (PH) (16, 17). One study
showed that citrulline plasma levels lower than 29 µmol/L were
predictive of PH secondary to BPD (18). The authors of this
study, Montgomery et al. ultimately propose that citrulline could
potentially serve as a therapeutic target for PH secondary to
BPD in preterm infants. Another study showed that a particular
arginase-1 single nucleotide polymorphism (SNP), rs2781666,
protects against the development of PH secondary to BPD by
increasing synthesis of nitric oxide and reducing urea synthesis
(19). In summary, results in both our discovery and replication
cohort studies show that urea cycle metabolites, particularly
citrulline, are closely related to BPD treatment response, and they
could potentially serve as predictors of BPD development and
response to dexamethasone therapy with further investigation.
Our replication study shares many of the strengths and
weaknesses with our discovery cohort. Once again, we recruited a
group of preterm infants with an even distribution of responders
and non-responders, and we were able to pair pre and post
treatment samples in most patients for analysis. NICU treatment
protocol was the same between studies, so mg/kg dosing of
dexamethasone was the same for both cohorts. An additional
strength is inherent to the nature of replication studies in that
we were able to support the findings of our discovery study
by replicating several of the results with equivalent analyses.
Lack of reproducibility is an ongoing crisis in many fields
of medical research. By reproducing several of the significant
findings of our discovery cohort study, we can begin to alleviate
these concerns and greatly strengthen the confidence in our
conclusions. Our study did again only involve untargeted
metabolomics analysis, which provides relative metabolite
abundance rather than absolute quantification. However, with a
set of reproducible findings of metabolites and their pathways
associated with dexamethasone response, we can approach the
design and selection of targeted metabolomics panels with greater
confidence. We are currently recruiting a large multi-site cohort
for targeted metabolomics analysis, building on the strengthened
findings from this study.
Metabolomics profiling continues to develop as a powerful
tool for hypothesis generation and investigation of the biological
mechanisms influencing response to pharmacotherapy. Since the
publication of our previous study, several additional articles
have been published on the relationship between metabolic
activity with BPD and its comorbidities, as referenced previously.
Metabolomics have been used to investigate several other disease
states relevant to the neonatal patient population as well (20–24).
Our findings contribute to this growing exploration of the link
between metabolism and variable treatment response in neonates
as well as strengthen several of the findings we have published
previously. Ultimately, pharmacometabolomics profiling has
the potential to discover powerful biomarkers than can be

suggesting that it could serve as an indicator for lung injury and
fibrosis (7). Our replication cohort study showed a consistently
significant association between trans-4-hydroxyproline levels
and dexamethasone treatment. The metabolite showed a fold
change of 0.6678 with a downward trend following treatment,
providing further evidence of the relationship between trans4-hydroxyproline and dexamethasone therapy. Since our first
metabolomics cohort study, additional articles have been
published on the subject of trans-4-hydroxyproline association
with pulmonary fibrosis. There are significantly elevated levels
of 4-hydroxyproline in exhaled breath analysis of idiopathic
pulmonary fibrosis patients as compared to control (8). Also,
serum 4-hydroxyproline, along with L-arginine, could serve as an
effective diagnosis biomarker for the early phase of pulmonary
fibrosis. This was further supported by showing that arctiin and
arctigenin can downregulate serum 4-hydroxyprogresterone
levels in cases of pulmonary fibrosis associated with silicosis (9).
With further evidence from our replication cohort as well as
additional published articles, trans-4-hydroxyproline continues
to be a promising potential marker for lung fibrosis and injury,
as well as drug response, in preterm infants at risk for BPD.
Gluconic acid lactone was significantly decreased in plasma
samples following dexamethasone treatment. This replicates
the results from the discovery cohort study, which showed a
substantial decrease of the free form of gluconic acid following
steroid treatment as well as a negative correlation with RSS
score in urine samples. Gluconic acid metabolism continues
to be poorly understood, and its role in BPD progression is
unclear. However, gluconate concentrations can influence the
hexose monophosphate shunt (10, 11). This shunt contributes to
the production of ribose-5-phosphate, which leads to nucleotide
synthesis through the pentose phosphate pathway. Interestingly,
our results also showed an association of multiple metabolites
in the pentose interconversion pathway with dexamethasone
therapy. These include xylulose, ribitol, and xylitol, which
were also significant in the discovery cohort study. The
repeat significant association of these metabolites suggest an
important role for the pentose phosphate pathway in response
to dexamethasone therapy. This is supported by multiple studies
that have proposed a connection between increased pentose
phosphate pathway (PPP) activity, pulmonary hypertension,
and BPD (12, 13). A recent study explored the relationship
between BPD related hyperoxia and PPP activity. The authors
found that hyperoxia caused increased PPP activity, which
induced abnormal endothelial cell development in neonatal mice
(14). Another recent study showed that glycolysis and PPP
induction by interleukin-1 beta co-occurred with induction of
pro-inflammatory signaling pathways in pulmonary tissues (15).
Our results show multiple metabolites involved in the
urea cycle of arginine biosynthesis significantly associated
with steroid therapy across both of our analyses. The prepost dexamethasone treatment analysis showed a significant
increase in the metabolite levels of urea in plasma samples and
aspartic acid in urine samples. The change in RSS correlation
analysis showed significant negative correlation of citrulline
levels in urine samples with RSS. Results of our discovery
cohort study also showed a significant association of citrulline
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collected during patient care in order to predict risk of disease
development and response to established pharmacotherapy for
the individual patient. Furthermore, identification of relevant
metabolites and their pathways can present new targets for the
development of novel therapies for this patient population. The
results of our study continue to expand on the investigation of
pharmacometabolomics in preterm infants and the strength of
reproducible results allow us to continue to narrow our focus
on the relevant metabolic pathways for improving treatment
outcomes in preterm infants with BPD.
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